Fenbendazole 222 mg 120 ct 99% purity

Fenbendazole 222mg Capsules — Standard Protocol Dose

Fenbendazole is a broad-spectrum benzimidazole anthelmintic with a long-established record in veterinary medicine and a rapidly growing body of human research. Originally developed and approved for use in dogs, cats, horses, and livestock, fenbendazole has attracted significant scientific interest over the past decade for its potential applications in human health — particularly oncology research. Each capsule in this product contains 222 mg of pharmaceutical-grade fenbendazole powder at 99.36% purity. The 222 mg dose corresponds precisely to the widely-referenced human off-label research protocol, making this the standard protocol dose for individuals exploring fenbendazole for investigational purposes.

Mechanism of Action

Fenbendazole exerts its effects through multiple complementary pathways, which has driven interest in its potential beyond veterinary antiparasitic use:

• Microtubule disruption via β-tubulin binding: Fenbendazole binds selectively to β-tubulin and disrupts microtubule polymerization — preventing formation of the mitotic spindle required for cell division. This is the same fundamental mechanism employed by several established chemotherapy agents; vinca alkaloids (e.g., vincristine, vinblastine) inhibit tubulin polymerization, while taxanes (e.g., paclitaxel) stabilize microtubules — both ultimately disrupting mitosis. Fenbendazole operates through the same target class.
• Glucose uptake inhibition: Fenbendazole moderately interferes with GLUT transporter function, reducing glucose uptake in both parasites and certain cancer cell lines. Cancer cells rely heavily on aerobic glycolysis (the Warburg effect) and are particularly sensitive to glucose deprivation.
• p53 stabilization: Research has demonstrated that fenbendazole can stabilize and activate p53 — a critical tumor suppressor protein that triggers apoptosis (programmed cell death) in damaged or abnormal cells. Many cancer cells exhibit dysregulated p53 pathways.
• Proteasomal interference: Fenbendazole has been shown to interfere with proteasomal function, disrupting the cellular protein degradation machinery that cancer cells depend on for survival and proliferation.

Anticancer Research

Interest in fenbendazole as a potential anticancer compound accelerated dramatically following the public account of Joe Tippens, a US patient diagnosed with stage 4 small cell lung cancer in 2016. Given a terminal prognosis, Tippens began a self-administered fenbendazole protocol alongside standard treatment. By 2018, his cancer was reportedly in complete remission, an outcome he attributed in part to fenbendazole. His story spread widely online and in South Korean media, spurring a wave of patient interest and prompting formal scientific investigation.

Peer-reviewed research on fenbendazole's anticancer properties includes:

• Dogra et al., 2018 (Scientific Reports): Demonstrated that fenbendazole causes mitotic arrest and apoptosis in human non-small cell lung cancer (NSCLC) cells. The study identified the triple mechanism of p53 stabilization, microtubule disruption, and interference with glucose metabolism as contributing to cancer cell death.
• Florio et al., 2019: Investigated fenbendazole's effects in glioblastoma (GBM) — one of the most treatment-resistant brain cancers — showing antiproliferative effects in glioblastoma cell models.
• Song et al., 2022: Contributed to the growing body of work examining fenbendazole in combination with other agents, consistent with the repurposed drug paradigm.
• Additional published studies have explored activity in colorectal cancer, ovarian cancer, and prostate cancer cell lines and animal models.

Fenbendazole is being actively studied as a repurposed drug — a compound already known to be safe in animals and with a well-characterized toxicity profile, evaluated for new indications alongside standard oncology treatments. It is not an approved cancer treatment in humans, and research is ongoing.

Veterinary Uses

Fenbendazole remains one of the most widely used and trusted broad-spectrum dewormers in veterinary practice worldwide. It is effective against:

• Dogs: Roundworms (Toxocara canis), hookworms (Ancylostoma, Uncinaria), whipworms (Trichuris vulpis), certain tapeworms (Taenia spp.), giardia, and lungworms.
• Cats: Roundworms (Toxocara cati), hookworms, giardia.
• Horses: Strongyles, ascarids, pinworms, and other equine intestinal parasites.
• Livestock and exotic animals: Widely used across species for gastrointestinal nematode infections.

The standard veterinary dosing guideline for dogs is approximately 50 mg per kg of body weight per day for 3 consecutive days.

Human Research Dosage Protocols

The most widely cited off-label human research protocol is the "Tippens Protocol":

• Dose: 222 mg fenbendazole per day (1 capsule of this product)
• Schedule: 3 days on, 4 days off (cycling weekly)
• Context: Often used alongside vitamin E succinate and bioavailable curcumin in the full Tippens stack, though fenbendazole is the central compound

The 222 mg dose in the Tippens Protocol is substantially lower than standard veterinary antiparasitic doses scaled for human body weight, and is thought to be well below levels associated with toxicity. Higher-dose protocols (e.g., 444 mg/day) are also being explored in some research contexts.

Always consult a qualified healthcare provider before beginning any off-label protocol. This product is not intended to diagnose, treat, cure, or prevent any disease.

Product Details

Safety & Side Effects

Fenbendazole has a well-established safety profile developed over decades of veterinary use. In human research contexts, it is generally considered well-tolerated at the doses used in common off-label protocols:

• Mild gastrointestinal effects (nausea, loose stools, diarrhea) may occur, particularly when starting use.
• Elevated liver enzymes (transaminases) have been reported with prolonged continuous use. Liver function monitoring is recommended for anyone using fenbendazole on an extended basis.
• The 3-days-on / 4-days-off cycling protocol is in part designed to reduce hepatic burden.
• Not recommended for use during pregnancy or breastfeeding without medical supervision.
• If you are on prescription medications or undergoing cancer treatment, consult your oncologist or physician before use — potential drug interactions should be evaluated.